华润双鹤：获得羟钴胺注射液药物临床试验批准通知书

Core Viewpoint - China Resources Double Crane (华润双鹤) has received approval from the National Medical Products Administration for clinical trials of Hydroxocobalamin Injection, aimed at treating metabolic disorders in children with methylmalonic acidemia, with or without homocystinuria [1] Group 1 - The company announced the receipt of the clinical trial approval notice on December 29 [1] - Hydroxocobalamin Injection is specifically indicated for pediatric patients suffering from metabolic disorders related to methylmalonic acidemia [1] - This development may enhance the company's product portfolio in the pediatric therapeutic area [1]